Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer

Journal of Clinical Oncology

Volumn 15, Issue 11, 1997, Pages 3394-3398

  Stadler, Walter M ^a   Kuzel, Timothy ^a   Roth, Bruce ^a   Raghavan, Derek ^a   Dorr, F Andrew ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GEMCITABINE;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CARCINOMA; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; EDEMA; FEMALE; FEVER; HUMAN; MALE; METASTASIS; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; TRANSITIONAL CELL CARCINOMA; URINARY TRACT CANCER;

EID: 0030698628     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.11.3394     Document Type: Article

References (29)

1. Sternberg CN, Yagoda A, Scher HI, et al: Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin, and cisplatin) for transitional cell carcinoma of the urothelium. J Urol 133:403-407, 1985
2. Sternberg CN, Yagoda A, Scher HI, et al: Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium: Efficacy and patterns of response and relapse. Cancer 64:2448-2458, 1989
3. Loehrer PJ, Einhorn LH, Elson PJ, et al: A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study. J Clin Oncol 10:1066-1073, 1992
4. Logothetis CJ, Dexeus FH, Finn L, et al: A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 8:1050-1055, 1990
5. Roth BJ, Bajorin DF: Advanced bladder cancer: The need to identify new agents in the post-MVAC (methotrexate, vinblastine, doxorubicin, and cisplatin) world. J Urol 153:894-900, 1995
6. Levine E, Raghavan D: MVAC for bladder cancer: Time to move forward again. J Clin Oncol 11:387-389, 1993
7. Saxman SB, Propert KJ, Einhorn LH, et al: Long-term follow-up of a phase II intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A Cooperative Group study. J Clin Oncol 15:2564-2569, 1997
8. Moore MJ, Iscoe N, Tannock IF: A phase II study of methotrexate, vinblastine, doxorubicin, and cisplatin plus recombinant human granulocyte-macrophage colony stimulating factors in patients with advanced transitional cell carcinoma. J Urol 150:1131-1134, 1993
9. Loehrer PJ, Elson P, Dreicer P, et al: Escalated dosages of methotrexate, vinblastine, doxorubicin, and cisplatin plus recombinant human granulocyte colony-stimulating factor in advanced urothelial carcinoma: An Eastern Cooperative Oncology Group trial. J Clin Oncol 12:483-488, 1994
10. Seidman AD, Scher HI, Gabrilove JL, et al: Dose-intensification of MVAC with recombinant granulocyte colony-stimulating factor as initial therapy in advanced urothelial cancer. J Clin Oncol 11:408-414, 1993
11. Logothetis CJ, Finn LD, Smith T, et al: Escalated MVAC with or without recombinant human granulocyte-macrophage colony-stimulating factor for the initial treatment of advanced malignant urothelial tumors: Results of a randomized trial. J Clin Oncol 13:2272-2277, 1995
12. Roth BJ, Dreicer R, Einhorn LH, et al: Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: A phase II trial of the eastern cooperative oncology group. J Clin Oncol 12:2264-2270, 1994
13. Einhorn LH, Roth BJ, Ansari R, et al: Phase II trial of vinblastine, ifosfamide, and gallium combination chemotherapy in metastatic urothelial carcinoma. J Clin Oncol 12:2271-2276, 1994
14. Witte R, Loehrer P, Dreicer R, et al: Ifosfamide in advanced urothelial carcinoma: An ECOG trial. Proc Am Soc Clin Oncol 12:230, 1993 (abstr)
15. Otaguro K, Ueda K, Niijima T, et al: Clinical evaluation of Z4942 (ifosfamide) for malignant urological tumors. Hinyokika Kiyo 27:459-462, 1981
16. Seidman AD, Scher HI, Heinemann MH, et al: Continuous infusion gallium nitrate for patients with advanced refractory urothelial tract tumors. Cancer 68:2561-2565, 1991
17. Crawford ED, Saiers JH, Baker LH, et al: Gallium nitrate in advanced bladder carcinoma: A Southwest Oncology Group study. Urology 38:355-357, 1991
18. Seligman PA, Crawford ED: Treatment of advanced transitional cell carcinoma of the bladder with continuous-infusion gallium nitrate. J Natl Cancer Inst 83:1582-1584, 1991
19. Witte RS, Elson P, Khandaker J, et al: An Eastern Cooperative Oncology Group phase II trial of trimetrexate in the treatment of advanced urothelial carcinoma. Cancer 73:688-691, 1994
20. Logothetis C, Dieringer P, Ellerhorst J, et al: A 61% response rate with 5-fluorouracil, interferon-α2b and cisplatin in metastatic chemotherapy-refractory transitional cell carcinoma. Proc Am Assoc Cancer Res 33:221, 1992 (abstr)
21. Bacoyiannis C, Skarlos D, Aravantinos G, et al: Cisplatin, interferon-α2B and 5-fluorouracil for advanced urothelial cancer: a phase II study. Proc Am Soc Clin Oncol 14:234, 1995 (abstr)
22. McCaffrey J, Hilton S, Mazumdar M, et al: A phase II trial of ifosfamide, paclitaxel, and cisplatin (ITP) in patients with advanced urothelial tract tumors. Proc Am Soc Clin Oncol 15:641, 1996 (abstr)
23. Abbruzzese JL, Grunewald F, Weeks EA, et al: A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 9:491-498, 1991
24. Abratt RP, Bezwoda WR, Falkson G, et al: Efficacy and safety profile of gemcitabine in non-small cell lung cancer: A phase II study. J Clin Oncol 12:1535-1540, 1994
25. Lund B, Hansen OP, Theilade K, et al: Phase II study of gemcitabine (2′,2′-difluorodeoxycytidine) in previously treated ovarian cancer patients. J Natl Cancer Inst 86:1530-1533, 1994
26. Burris III HA, Moore MS, Andersen J, et al: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreatic cancer: A randomized trial. J Clin Oncol 15:2403-2413, 1997
27. Pollera CF, Ceribelli A, Crecco M, et al: Weekly gemcitabine in advanced bladder cancer: A preliminary report from a phase I study. Ann Oncol 5:182-184, 1994
28. Moore MJ, Tannock I, Ernst S, et al: Gemcitabine demonstrates promising activity as a single agent in the treatment of metastatic transitional cell carcinoma. Proc Am Soc Clin Oncol 15:637, 1996 (abstr)
29. Delena M, Larusso V, Amadori D, et al: Gemcitabine in resistant stage IV bladder cancer: A phase II study. Eur J Cancer 31A:1146, 1995 (abstr)